Benzinga

Benzinga Japan

Benzinga

Benzinga Japan

Benzinga

Benzinga Japan
土曜日, 9 05

Cytokinetics Inc

CYTKNASDAQ
Trade with Public
Trade with Public
$72.72
-1.23-1.66%
近くで: Sep 4, 5:00 PM EST
$72.72
N/A
時間外: Sep 4, 4:00 PM EST
概要ニュース業績予想イベント目標株価財務センチメント株主構成比較オプション株式レポート

Cytokinetics Financials

Cytokinetics (CYTK) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Cytokinetics Q2 EPS $(1.50) Beats $(1.63) Estimate, Sales $28.624M Beat $17.382M Estimate

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which beat the analyst consensus estimate of $(1.63) by 7.98 percent. This is a 33.93 percent decrease over losses of $(1.12) per share from the
Benzinga Newsdesk

PRO
Cytokinetics Q1 EPS $(1.67) Misses $(1.64) Estimate, Sales $19.355M Beat $8.518M Estimate.

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.67) per share which missed the analyst consensus estimate of $(1.64) by 1.83 percent. This is a 22.79 percent decrease over losses of $(1.36) per share from the
Benzinga Newsdesk

Earnings Scheduled For May 5, 2026

Benzinga Insights

Cytokinetics Q4 Earnings Summary & Key Takeaways

Benzinga Insights

PRO
Cytokinetics Q4 EPS $(1.50) Misses $(1.45) Estimate, Sales $17.755M Beat $6.911M Estimate

Cytokinetics (NASDAQ:CYTK) reported quarterly losses of $(1.50) per share which missed the analyst consensus estimate of $(1.45) by 3.45 percent. This is a 19.05 percent decrease over losses of $(1.26) per share from the
Benzinga Newsdesk

Earnings Scheduled For February 24, 2026

Benzinga Insights

データとAPI: Benzinga API · 株式ニュースAPI · アナリスト評価API · 企業ロゴAPI

Benzinga

Benzinga Japan

ニュース

パートナーシップ

ベンジンガ・グローバル

© 2026 Benzinga | All Rights Reserved